公开(公告)号：US20130189287A1

公开(公告)日：2013-07-25

申请号：US13725382

申请日：2012-12-21

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Eliane Fischer ,  Laurent Gauthier ,  Francois Romagné ,  Roger Schibli

IPC: C07K19/00 ,  C12P21/00 ,  C12N9/10 ,  C07C323/60 ,  C07C323/12 ,  C07C247/04 ,  C07D225/08 ,  C07C217/08 ,  C07C229/26 ,  C07C233/62 ,  C07D277/06 ,  C07F9/50 ,  C07D257/08 ,  C07C223/02 ,  G01N33/68

CPC classification number: A61K47/6803 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6865 ,  A61K47/6871 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/5022 ,  C07K16/00 ,  C07K19/00 ,  C07K2317/40 ,  C12N9/1044 ,  C12P21/005 ,  G01N33/6854

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions

Abstract translation: 本申请涉及用于免疫球蛋白功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法

公开(公告)号：US20240199750A1

公开(公告)日：2024-06-20

申请号：US18283385

申请日：2022-03-24

Applicant: INNATE PHARMA

Inventor： Stephanie CORNEN ,  Laurent GAUTHIER ,  Yannis MOREL ,  Olivier DEMARIA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C12N5/0783

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K14/54 ,  C07K14/5418 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K16/2803 ,  C07K16/283 ,  C12N5/0646 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multi-specific proteins that bind to NKp46 and a cytokine receptor on NK cells, and optionally that further bind CD16A on NK cells, and that also bind to an antigen of interest (e.g. a cancer antigen) on a target cell (e.g. a cancer cell). The multi-specific proteins are capable of increasing NK cell cytotoxicity toward a target cell that expresses the antigen of interest (e.g., a cell that contributes to disease, a cancer cell).

公开(公告)号：US11970535B2

公开(公告)日：2024-04-30

申请号：US17114835

申请日：2020-12-08

Applicant: INNATE PHARMA

Inventor： Carine Paturel ,  Helene Sicard

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/3061 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US20240117045A1

公开(公告)日：2024-04-11

申请号：US18491836

申请日：2023-10-23

Applicant: INNATE PHARMA

Inventor： AGNÈS BOYER-CHAMMARD ,  PIERRE DODION ,  ROGER COHEN

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2863 ,  C07K16/30 ,  A61K2039/507

Abstract: This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.

公开(公告)号：US20240117042A1

公开(公告)日：2024-04-11

申请号：US18285668

申请日：2022-04-04

Applicant: INNATE PHARMA

Inventor： BENJAMIN ROSSI ,  STÉPHANIE CHANTEUX ,  ROMAIN REMARK ,  CÉCILE BONNAFOUS ,  CLARENCE DEFFAUD ,  THIBAUT PELAT

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K2317/622

Abstract: The present invention relates to antibodies and methods for detecting KIR3DL2 expression in paraffin-embedded tissue samples. Also provide are methods of making antibodies, antibody fragments, and derivatives thereof that specifically bind to their target antigen in paraffin-embedded tissue samples.

公开(公告)号：US11891444B2

公开(公告)日：2024-02-06

申请号：US17315547

申请日：2021-05-10

Applicant: INNATE PHARMA

Inventor： Laurent Gauthier ,  Nadia Anceriz ,  Ariane Morel ,  Benjamin Rossi

IPC: C07K16/28 ,  C07K16/46 ,  C12N15/66 ,  C12N15/64 ,  C12N5/10 ,  C12N15/00

CPC classification number: C07K16/2803 ,  C07K16/2809 ,  C07K16/2887 ,  C07K16/468 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/526 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/92 ,  C12N2511/00 ,  C12N2523/00

Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20230416383A1

公开(公告)日：2023-12-28

申请号：US18308778

申请日：2023-04-28

Applicant: INNATE PHARMA ,  SANOFI

Inventor： Marielle CHIRON ,  Angela Virone-Oddos ,  Laurent Gauthier

IPC: C07K16/28 ,  A61P35/02 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61P35/02 ,  A61K39/395 ,  A61K39/3955 ,  C07K16/2896 ,  A61K2039/505

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

公开(公告)号：US11795222B2

公开(公告)日：2023-10-24

申请号：US16979323

申请日：2019-03-12

Applicant: INNATE PHARMA

Inventor： Agnes Boyer-Chammard ,  Pierre Dodion ,  Roger Cohen

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  C07K16/30

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/2863 ,  C07K16/30 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.

公开(公告)号：US20230296611A1

公开(公告)日：2023-09-21

申请号：US18020436

申请日：2021-08-06

Applicant: INNATE PHARMA

Inventor： MARION BENEZECH ,  ROMAIN REMARK

IPC: G01N33/574 ,  G01N33/569 ,  C07K16/28

CPC classification number: G01N33/57492 ,  G01N33/56977 ,  C07K16/2833 ,  G01N2800/52 ,  C07K2317/31

Abstract: The present disclosure relates to research and diagnostic tools to specifically detect MICA and MICB polypeptides in paraffin embedded tissue samples. The disclosure also relates to methods of using the tools to detect MICA and MICB polypeptides, notably in tumor tissue.

公开(公告)号：US20230235060A1

公开(公告)日：2023-07-27

申请号：US18164649

申请日：2023-02-06

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

CPC classification number: C07K16/2818 ,  C07K16/2803 ,  C07K16/2827 ,  A61K39/39558 ,  C07K16/30 ,  A61K2039/507

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.